Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.67 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22703367 | 0.92 | LIPE (0.75) | LIPEMRGPRX4MAPTL3MBTL1TDP1 | |
| SCHEMBL24839941 | 0.87 | LIPE (0.55) | LIPEMRGPRX4MAPTL3MBTL1TDP1 | |
| SCHEMBL416462 | 0.85 | MAPT (0.57) | LIPEMRGPRX4MAPTL3MBTL1TDP1 | |
| SCHEMBL29380769 | 0.85 | MAPT (0.57) | LIPEMRGPRX4MAPTL3MBTL1TDP1 | |
| SCHEMBL28594857 | 0.84 | LIPE (0.55) | LIPEMAPTL3MBTL1TDP1MAPK1 | |
| SCHEMBL10017145 | 0.82 | ALDH1A1 (0.46) | LIPEMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL29955819 | 0.81 | LIPE (0.65) | LIPEMAPTL3MBTL1TDP1MAPK1 | |
| SCHEMBL22703336 | 0.81 | LIPE (0.55) | LIPEMAPTL3MBTL1TDP1MAPK1 | |
| SCHEMBL3157216 | 0.80 | MRGPRX4 (0.66) | MRGPRX4MAPTL3MBTL1TDP1MAPK1 | |
| SCHEMBL132403 | 0.80 | LIPE (1.00) | LIPEMAPTL3MBTL1TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151991-A1 | RNAI AGENTS FOR INHIBITING INFLUENZA A VIRAL GENE EXPRESSION, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2023183814-A2 | SUBCUTANEOUS DELIVERY OF RNAI AGENTS FOR INHIBITING EXPRESSION OF RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) | Arrowhead Pharmaceuticals, Inc. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230265437-A1 | RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265437-A1 | RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023150622-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF CORONAVIRUS (COV) VIRAL GENOMES, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023070082-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF MATRIX METALLOPROTEINASE 7(MMP7), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230013022-A1 | RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-01-19 | — | — | US | disclosed |
| US-20230002767-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-01-05 | — | — | US | disclosed |
| US-20220396791-A1 | RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-12-15 | — | — | US | disclosed |
| WO-2021086995-A1 | RNAI AGENTS FOR INHIBITING EXPRESSION OF BETA-ENAC, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN ADAMS (US) | 2001-12-06 | — | — | US | disclosed |
| EP-1155000-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| US-20010014689-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN A (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1109556-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6211208-B1 | INHIBITION OF NITRIC OXIDE SYNTHETASE, ANTIINFLAMMATORY AGENTS | PFIZER INC | 2001-04-03 | — | — | US | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000050400-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-1007520-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000009130-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999010339-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265437-A1 | RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use | MMP7, MMP1, MMP17 | LIPE 3815/4885MRGPRX4 1681/4885MAPT 3643/4885 |
| US-20220396791-A1 | RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use | AGER, ASGR1, TLR3 | LIPE 3019/4885MRGPRX4 187/4885MAPT 3478/4885 |
| US-20230013022-A1 | RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use | SCNN1B, SCNN1A, SCNN1G | LIPE 4590/4885MRGPRX4 1865/4885MAPT 3168/4885 |
| US-20010014689-A1 | 2-aminopyridines containing fused ring substituents | CBR1, CBR3, NOS2 | LIPE 4692/4885MRGPRX4 2840/4885MAPT 3855/4885 |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | LIPE 4640/4885MRGPRX4 1741/4885MAPT 1362/4885 |
| US-20230002767-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | MUC1, ALG1, RNASE1 | LIPE 3036/4885MRGPRX4 168/4885MAPT 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.